Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

September 29th 2023

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

September 27th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Dr Hwang on Considering AEs Associated With FDA-Approved Agents in Nonmetastatic Prostate Cancer

September 15th 2023

Clara Hwang, MD, discusses adverse effects associated with FDA-approved agents for patients with nonmetastatic prostate cancer.

Dr Hwang on Unmet Needs Remaining in Nonmetastatic Prostate Cancer

September 13th 2023

Clara Hwang, MD, discusses unmet needs in patients with nonmetastatic prostate cancer who then progress on novel agents and develop metastatic disease.

EMA Validates Type II Variation Application for Enzalutamide in Nonmetastatic Hormone-Sensitive Prostate Cancer

September 13th 2023

The European Medicines Agency has validated its Type II variation for enzalutamide as an option in patients with nonmetastatic hormone-sensitive prostate cancer at high risk of biochemical recurrence who are not suitable for salvage radiotherapy.

Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC

September 11th 2023

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Dr Hwang on Risk-Stratification Factors in Nonmetastatic Prostate Cancer

September 6th 2023

Clara Hwang, MD, discusses risk stratification methods used to assess the risk of metastatic disease in patients with nonmetastatic prostate cancer.

Dr Hwang on FDA-Approved Agents for nmCRPC

September 5th 2023

Clara Hwang, MD, highlights agents that the FDA has approved for use in patients with nonmetastatic castration-resistant prostate cancer, such as apalutamide, enzalutamide, and darolutamide.

Dr Sokolova on the Importance of Genetic Testing in Prostate Cancer

August 31st 2023

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Ongoing Clinical Trials in the Metastatic CRPC Setting

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Dr Agarwal on the Benefit of PARP Inhibitors vs Chemotherapy in mCRPC

August 28th 2023

Neeraj Agarwal, MD, discusses the benefit of PARP inhibitors compared with chemotherapy in patients with metastatic castration-resistant prostate cancer.

Dr Reichert on Key Research Questions in Prostate Cancer

August 25th 2023

Zachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.

Dr Vaishampayan on the Use of Talazoparib and Enzalutamide in Patients With HRR Gene–Mutated mCRPC

August 24th 2023

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.

Olaparib Plus Abiraterone Acetate Receives Japanese Approval for BRCA-Mutant mCRPC

August 24th 2023

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Dr Reichert on Investigating Novel Agents and Pathways in Prostate Cancer

August 23rd 2023

Zachery Roger Reichert, MD, PhD, discusses the effects novel agents and pathways have had on the treatment of patients with prostate cancer.

FDA Grants Priority Review to Enzalutamide for nmCSPC With High-Risk Biochemical Recurrence

August 23rd 2023

The FDA has accepted and granted priority review to a supplemental new drug application seeking the approval of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

Dr Alumkal on Triplet Therapy in Prostate Cancer

August 22nd 2023

Joshi Alumkal, MD, discusses the use of triplet therapy in prostate cancer.

Potential for CDK4/6 Inhibitors in Metastatic CRPC

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

Atezolizumab Plus Cabozantinib Improves PFS in Hormone Therapy–Pretreated mCRPC

August 21st 2023

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.